Interleukin Genetics Retains Top Life Science Communications Firms
03/18/2008
Interleukin Genetics Retains
Top Life Science Communications Firms
Stern Investor Relations and LaVoie Group Selected as IR, PR Agencies of Record
Waltham, MA – March 18, 2008 – Interleukin Genetics, Inc., (AMEX:ILI), announced today that it has retained two premier life science communications firms, Stern Investor Relations, Inc., and LaVoie Group, as agencies of record to provide investor relations and public relations services, respectively.
The two firms will provide strategic counsel and execution, will lead efforts to communicate Interleukin Genetics’ vision to use the science of applied genetics to personalize health management and will support the Company’s strategy to establish additional partnerships and relationships with biotechnology and pharmaceutical companies.
Lewis H. Bender, Chief Executive Officer commented, “Interleukin Genetics has a strong message on the value of diagnostic testing to empower consumers to personalize their health. With the addition of these two firms, I am confident that we will deliver our message more effectively to our key constituencies.”
About LaVoie Group
LaVoie Group provides strategic, integrated marketing and communications—including marketing strategy, corporate communications, as well as public and investor relations to life sciences and healthcare companies. LaVoie Group’s clients range from start-ups to industry leaders. For more information, visit www.lavoiegroup.com.
About Stern Investor Relations
Stern Investor Relations provides investor relations consulting services to biotechnology and healthcare companies. Stern IR develops and implements strategic investor relations programs designed to effectively manage communications with the investment community. Founded in 1998, Stern IR offers a full range of investor relations services. For more information, please visit www.sternir.com.
About Interleukin Genetics
Interleukin Genetics, Inc. (AMEX:ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. The Company currently offers an array of Nutraceuticals and OTCeuticals®, including Ginkoba®, Ginsana® and Venastat® which are sold at the nation’s largest food, drug and mass retailers. Interleukin is headquartered in Waltham, MA. For more information about Interleukin and its ongoing programs, please visit www.ilgenetics.com.
# # #
Media:
Catherine Cloft
LaVoie Group
978-745-4200 x107
ccloft@lavoiegroup.com
Investor Relations:
Melanie Friedman
Stern Investor Relations
212-362-1200
melanie@sternir.com